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Abstract
Background: There is ample evidence that patients with
CKD have an increased risk of osteoporotic fractures. Bone
fragility is not only influenced by low bone volume and mass
but also by poor microarchitecture and tissue quality. More
emphasis has been given to the quantitative rather than
qualitative assessment of bone health, both in general population and CKD patients. Although bone mineral density
(BMD) is a very useful clinical tool in assessing bone strength,
it may underestimate the fracture risk in CKD patients. Serum
and urinary bone biomarkers have been found to be reflective of bone activities and predictive of fractures independently of BMD in CKD patients. Bone quality and fracture risk
in CKD patients can be better assessed by utilizing new technologies such as trabecular bone score and high-resolution
imaging studies. Additionally, invasive assessments such as
bone histology and micro-indentation are useful counterparts in the evaluation of bone quality. Summary: A precise
diagnosis of the underlying skeletal abnormalities in CKD patients is crucial to prevent further bone loss and fractures. We
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must consider bone quantity and quality abnormalities for
management of CKD patients. Here in this part I, we are focusing on advances in bone quality diagnostics that are expected to help in proper understanding of the bone health
in CKD patients. Key Messages: Assessment of bone quality
and quantity in CKD patients is essential. Both noninvasive
and invasive techniques for the assessment of bone quality
are available.
© 2021 The Author(s)
Published by S. Karger AG, Basel

Introduction

CKD affects 8–10% of the population [1]. The fracture
risk in CKD patients increases with worsening kidney
function, suggesting specific CKD-related causes. Bone
disease is a major complication of CKD and is a manifestation of CKD-mineral bone disorder. Renal osteodystrophy (ROD) is an alteration of bone morphology in patients with CKD and is a measure of the skeletal compo-
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PROS

CONS

PTH & bone
turnover markers

• Noninvasive
• Aids in prediction of bone turnover

• Because of renal clearance, osteocalcin, P1NP and CTX has limited use in CKD

BMD- DEXA

• Widely available and noninvasive
• Low radiation exposure & used in FRAX
• Correlates with cortical porosity in CKD

• Unable to assess type of ROD
• Assess areal density only
• Cannot distinguish cortical from trabecular bone

Trabecular bone
score

• Noninvasive, Independent fracture predictor
• Can be applied retrospectively to DEXA
• No extra radiation, time and expense

• Cannot detect type of ROD
• Image noise degrades resolution
• Variability among various software's

Quantitative
ultrasound

• Non invasive with no radiation exposure
• Portable
• Correlates with BMD-DEXA

• Only at distal extremity sites
• Inter-observer variability
• Lack of fracture predictability data in CKD

QCT

• 3D volumetric assessment of spine and femur
• Not affected by extra skeletal calcification

• High radiation exposure
• Expensive and cannot detect type of ROD

HRpQCT

• Assesses microarchitecture noninvasively
• Good cortical and trabecular differentiation
• Correlates with bone histopathology

• Expensive and not widely available
• Investigational tool only
• Only distal extremity site (tibia and radius)

HR-MRI

• Non-ionizing
• Can image central bones (hip)

• Expensive
• Not widely available

Finite element
analysis (FEA)

• Improves bone quality assessment by CT and MRI
• Aids CT and MRI in evaluating mechanical properties & fracture prediction

• Lack of standardization
• Various loading conditions can affect the estimation of strength

Reference point
indentation

• Good in-vivo measure of bone stiffness & quality
• Correlates well with fracture risk
• Correlates with BMD and TBS in CKD

• Invasive and can cause local complications
• Does not represent whole bone strength
• Does not detect type of ROD

Bone biopsy

• Gold standard as it directly assesses bone turnover, mineralization and
volume
• Assess bone marrow, can detect heavy metals and micro-cracks

• Invasive and cannot detect whole bone strength
• Not widely available and needs expertise

FTIR &
nano-indentation

• Provides data on bone material properties
• Adds additional information about bone quality

• Limited availability and needs bone tissue
• Only provides relative measures of mineral/matrix etc

Fig. 1. The pros and cons of each method of bone quality assessment in CKD patients.

nent of the systemic disorder of CKD-mineral bone
disorder, which is quantifiable by histomorphometry [2].
Because of the ease of use and widespread availability
of dual-energy X-ray absorptiometry (DEXA), operationally the World Health Organization (WHO) defined
osteoporosis as a reduction in bone mineral density
(BMD) t scores of ≥2.5 standard deviations from the
mean value in young adults [3]. This definition is now
routinely used worldwide in clinical practice for the diagnosis of osteoporosis. Fractures may also occur, however,
with low-energy trauma in non-osteoporotic patients, as
classified based on their BMD t scores [4–6]. In 2000, the
NIH defined osteoporosis as “a skeletal disorder characterized by compromised bone strength predisposing to an
increased risk of fracture.” Bone strength reflects the integration of 2 main components: bone quantity and bone
quality [7].
Thus, bone quantity (assessed by DEXA to give 2-dimensional areal BMD or with quantified 3-dimensional
quantitative computed tomography [QCT] for volume)
is only one component. Bone quality is a second major
component and includes bone remodeling abnormalities,
collagen cross-linking, and mineralization properties.
2
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Remodeling abnormalities are generally evaluated with
bone biopsy and dynamic histomorphometry (tetracycline labeling), and such abnormalities are nearly universal in patients with CKD [8].
WHO developed a Fracture Risk Assessment Tool
(FRAX) in the general population [9]. The addition of
BMD to the FRAX score improves the prediction of fracture risk; however, bone quality is not included in this
tool. There is an option to say yes or no to secondary osteoporosis; however, this does not include CKD. It might
be useful to add bone quality measurement in the general
population and the CKD as a secondary cause of osteoporosis to improve fracture risk prediction.
Bone quality can be evaluated by studying bone volume, microarchitecture, material properties, and microdamage. All these factors can be assessed at macro, micro,
and nano hierarchical levels by various diagnostic modalities [10]. Of the spectrum of methods available to assess bone quality from several different perspectives, we
describe the clinically relevant ones. The pros and cons of
each method of bone quality assessment in CKD patients
are included in Figure 1.
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PTH and Bone Turnover Markers

Bone turnover markers (BTMs) give an idea of the
bone resorption and bone formation rate. They provide
an integrated dynamic assessment of skeletal metabolism
and facilitate ROD management [11]. Bone formation
markers including bone-specific alkaline phosphatase
(BSAP), osteocalcin, and procollagen type-1 N-terminal
propeptide (P1NP) are markers of osteoblast function.
Bone resorption markers such as tartrate-resistant acid
phosphatase 5b (Trap-5b) and C-terminal telopeptides of
type I collagen (CTX) are markers of osteoclast function.
BSAP and Trap-5b are not cleared by the kidneys, hence
used in CKD patients. On the other hand, osteocalcin,
P1NP monomer, and CTX are cleared by the kidneys, and
their usefulness in CKD patients remains unclear. Serum
intact PTH (iPTH) and BSAP are the most commonly
used turnover markers to discriminate renal bone disease. In dialysis patients, Sprague et al. [12] reported that
iPTH and whole PTH (wPTH) level of <2 times the upper
limit of normal had a sensitivity of 65 and 74% and a specificity of 67 and 57%, respectively, for low-turnover bone
disease (LTBD). iPTH and wPTH of >9 times the upper
limit of normal showed a sensitivity of 37 and 31% and a
specificity of 86 and 88%, respectively, for high-turnover
bone disease (HTBD) [12]. Monier-Faugere et al. [13]
studied PTH-(1–84)/-(7–84) ratio. They found that a ratio of >1 had 100% sensitivity for HTBD, and a ratio of <1
had 100% sensitivity for LTBD. Ureña et al. [14] demonstrated that BSAP >20 and <20 ng/mL has 100% sensitivity and specificity for HTBD and LTBD, respectively, in
hemodialysis (HD) patients.
BTMs also assist in bone loss and fracture risk prediction in CKD patients. In a cross-sectional study, Nickolas
et al. reported that osteocalcin, P1NP, and Trap-5b discriminated fracture status in pre-dialysis CKD patients
independent of BMD. They also noted a strong relationship between iPTH and BTMs, trabecular volumetric
BMD, and microarchitecture compared to cortical volumetric BMD or thickness. They explained this by the effect of hyperparathyroidism preferentially on the metabolically active trabecular bone [15]. However, the same
group, in a more recent longitudinal study of CKD patients (including dialysis), showed that hyperparathyroidism and high BTMs were associated with decreased
cortical density and thickness but not with trabecular
changes [16].
Laowalert et al. [17] in a recent study found that serum
iPTH >484.5 or TRAP-5b >1.9 pg/mL has 92% sensitivity
and 50% specificity for prediction of HTBD in Asian HD
Assessment of Bone Quality in CKD
Patients

patients. The sensitivity goes down to 58% but the specificity goes up to 100% when they combined both. Limori
et al. [18] found that iPTH levels of <150 or >300 pg/mL
along with higher BSAP levels (>19.9 μg/L) were associated with a higher fracture risk in ESRD. Perrin et al. [19]
reported that iPTH levels ≥130 pg/mL at 3 months posttransplantation predicted incident fractures in kidney
transplant recipients.
In our laboratory, we previously studied FGF23 as a
potential bone marker in adult dialysis patients. FGF23
correlated well with mineralization parameters. Patients
with very high FGF23 levels had normal mineralization
lag time [20]. Activin A is considered a regulator of bone
turnover and is one of the markers of increased osteoclast
activity [21]. Our group previously reported that serum
activin A is one of the first biomarkers that goes up in
ROD and correlates well with bone turnover [22].
Sclerostin levels increase with CKD progression, and
its serum levels are associated with cardiovascular events
[23, 24]. Osteocytes are the main source of sclerostin,
though kidney, liver, and vascular wall can secrete it too
[25]. Mare et al. [26] reported a negative correlation between skeletal and circulating sclerostin levels with histomorphometric measures of bone turnover. Cejka et al.
[27] previously described a promising role of serum
sclerostin level in addition to iPTH in the diagnosis of
HTBD in dialysis patients. Furthermore, Malluche et al.
[28] found that baseline serum sclerostin and Trap-5b
levels predicted bone loss. Circulating sclerostin is dialyzable, so timing of blood draw is crucial while interpreting
the results in dialysis patients [29]. Furthermore, in patients undergoing peritoneal dialysis, sclerostin is present
in very high concentrations in the peritoneal fluid [30].
Thus, the utility of serum sclerostin as a BTM in CKD,
especially in HD and peritoneal dialysis patients, is yet to
be determined.
DEXA Scans: BMD and Trabecular Bone Score

It is challenging to diagnose osteopenia based on plain
radiographs. Conventional X-ray films are insensitive to
the changes in BMD. Patient might lose up to 50% of bone
mass before it can be detected on a lumbar radiography
[31]. Moreover, it is a subjective rather than objective tool
with a significant interobserver variabilities. The agreement between the readers for the diagnosis of osteopenia
based on X-ray was achieved only in 43% of all radiographs [32].
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Although it is widely available and a good test for bone
quantity, DEXA areal BMD does not detect the type of
ROD in CKD patients and cannot evaluate bone quality.
Other limitations of DEXA scans include the confounding effects of surrounding soft tissue, bone artifacts caused
by osteoarthritis, degenerated disks, vertebral compression fractures, and aortic calcification, which are not uncommon in CKD patients. However, femoral BMD is
correlated with cortical porosity histomorphologically in
dialysis patients [33]. Because DEXA is a 2-dimensional
technique, it also cannot be used to measure true volumetric BMD (vBMD) and bone size or to separate trabecular from cortical bone. Thus, a large bone will yield a
higher areal BMD than a small bone, although the vBMD
would be the same.
Fractures occur in 30–50% of people with normal
BMD. This might be due to lack of capturing of poor bone
quality by DEXA scans. Trabecular bone score (TBS) captures vertebral trabecular texture from the lumbar DEXA
images [34]. It is a noninvasive tool to assess bone microarchitecture. TBS does not add any extra time, cost, or
radiation exposure to the DEXA scans. The TBS software
can be applied retrospectively to BMD images to better
assess the bone quality and thus the fracture risk. TBS
software has been modified over the past few years. TBSv1 algorithm was the initial software utilized to assess
bone quality, which was developed after studies on females with average body habitus. The reference values
could not correlate well in male population or people with
a BMI of <15 or >35. TBS-v2 algorithm was developed to
counter the shortcomings of the previous TBS version,
and it has improved the fracture prediction [35].
Certain conditions like CKD, diabetes, obesity, and
long-term glucocorticoid use have increased fracture risk
despite normal BMD. All these conditions affect bone
quality, particularly trabecular microarchitecture. TBS
can be extremely helpful in predicting fracture risk and
assessment of bone quality in these circumstances [36–
38]. TBS is usually low in patients with CKD including
dialysis patients [39]. TBS correlated better with incidence of fracture in pre-dialysis CKD, dialysis patients,
and kidney transplant recipients, as compared to BMD
[40, 41]. In a multivariate analysis in ESRD patients by
Ramalho et al. [42], TBS was correlated with trabecular
bone volume and trabecular width histopathologically.
However, Holloway-Kew et al. [43] found that TBS and
BMD did not correlate with prior history of fractures in
CKD patients compared to micro-indentation parameters.
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Perez-Saez et al. [44] reported that despite a persistent
decline in the BMD, TBS and bone quality stayed normal
up to 10 years after kidney transplantation. Furthermore,
Silva et al. [40] previously reported that TBS can be used
as a tool to assess the response to different therapeutic
interventions. They demonstrated a maximal TBS improvement with teriparatide followed by denosumab and
tamoxifen, then bisphosphonates in older women.
Quantitative Ultrasound

Quantitative ultrasound (QUS) machines employ
waves with lower frequencies compared to the conventional soft tissue US. The studied skeletal sites are the distal metaphysis of the phalanx, the calcaneus, the radius,
and the tibia. All these sites are predominantly cortical
bone, except the calcaneus, which is mainly composed of
trabecular bone [45].
As QUS waves propagate through the bone, their velocity reflects the material properties of the bone such as
its density, architecture, and elasticity. The degree of attenuation of the wave amplitude, measured by broadband
ultrasound attenuation, is influenced by trabecular separation and other structural characteristics of trabecular
bone. Several other more complex wave parameters such
as shape (number of peaks), bone transmission time, and
amplitude-dependent speed of sound (SOS) have been
developed, and these have been correlated with several
bone properties measured by micro-CT [46].
In the 1990s, studies on QUS showed that SOS measured in bones such as tibia inversely correlated with dialysis vintage and iPTH levels [47]. Similarly, in a study
employing phalangeal QUS in HD patients, amplitudedependent SOS was significantly lower compared to control groups, and it was negatively correlated with iPTH
levels [48]. Furthermore, HD patients had reduced calcaneal broadband ultrasound attenuation and SOS scores
compared to controls, and there was a significant association between calcaneal QUS parameters and DEXA
scans [49]. QUS measures have been correlated with
DEXA at both phalanges and calcaneus [50, 51]. In osteoporotic patients, QUS measurements have been used to
monitor the effects of treatment with alendronate, raloxifene, and teriparatide [45]. Ten-year fracture risk
probabilities have been calculated using QUS measures in
osteoporotic patients [52]. However, the predictive value
for CKD patients has not been studied, and it is an interesting potential topic for future research. It might also
have an application in monitoring of therapy in ROD.
Asadipooya/Abdalbary/Ahmad/Kakani/
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Quantitative Computed Tomography

QCT is an in vivo diagnostic modality that can be applied to the axial or appendicular skeleton, where large
body segments such as hip or spine are imaged to measure
vBMD. One of the main advantages of QCT, particularly
in CKD patients, is that it is not confounded by the presence of extra-osseous calcium, which can be a problem
with DEXA scans. It also better identifies bone loss over
time compared to DEXA in HD patients [53]. The disadvantages of this method include high radiation exposure
and cost and it does not assess the type of ROD.
High-Resolution Peripheral Quantitative Computed
Tomography

High-resolution peripheral quantitative computed
tomography (HRpQCT) is another tool that employs
narrower slice width and field of view compared to QCT
and maximizes spatial resolution using image reconstruction algorithms. It is a good tool to assess bone microarchitecture (cortical porosity and trabecular connectivity) and vBMD at distal extremity sites such as distal
radius and tibia. It provides more detailed information
about bone microstructure than QCT, which does not
detect trabecular thickness or cortical porosity [10].
Measurement of bone microarchitecture by HRpQCT in
addition to BMD can explain the variance in bone
strength. Studies using HRpQCT have demonstrated a
preferential loss of cortical bone in CKD patients [16]. In
CKD stages 2–4, before the onset of secondary hyperparathyroidism (SHPT), impairment of trabecular bone
is noted with HRpQCT, and this could explain the increased risk of fractures in early CKD. As CKD progresses and SHPT ensues, with increased turnover, bone loss
assessed by HRpQCT is predominantly cortical and is
highly associated with fractures in weight-bearing and
non-weight-bearing sites [16, 54]. Measures of bone microarchitecture obtained by HRpQCT have been validated against bone micro-CT [55]. Nickolas et al. [15] in a
cross-sectional study in pre-dialysis patients demonstrated that several HRpQCT measures of microarchitecture were significantly lower in patients with fractures. In
CKD patients with HTBD and osteoporosis, there is cancellization of endocortical bone. This cancellization can
confound cortical measurements obtained by HRpQCT
and can lead to errors in quantifying changes in trabecular and cortical morphology [56].

Assessment of Bone Quality in CKD
Patients

High-Resolution Magnetic Resonance Imaging or
Micro-Magnetic Resonance Imaging

High-resolution magnetic resonance imaging (HRMRI) or micro-MRI is a noninvasive and nonionizing
method for the quantification of bone microarchitecture.
Whereas HRpQCT is limited to places like ankle and
wrist, HR-MRI can measure other sites like the proximal
femur. In a small cross-sectional study in patients with
ROD, MRI indices of trabecular network integrity correlated with histomorphometric trabecular bone volume,
separation, and thickness. HR-MRI parameters also correlated with trabecular separation measured by micro-CT
and turnover indices [57]. Parameters of bone microarchitecture obtained by both HR-MRI and HRpQCT have
been correlated with bone strength using finite element
analysis (FEA) [58, 59].
Finite Element Analysis

FEA is a computational method that provides information on bone quality, microarchitecture, fracture risk,
and mechanical properties. It can be generated through
QCT, HRpQCT, or MRI data. CT-based FEA improved
assessment of bone strength compared to DXA or QCT
but is not standardized, and variability in loading conditions can affect the strength estimates [60, 61]. MRI-based
FEA improved diagnosis precision, predicted fracture,
and was useful for monitoring bone loss and response to
treatment [61]. HRpQCT-based FEA cortical thickness
and volume correlated with BTMs, while cortical porosity correlated with PTH in a cross-sectional study in
ESRD patients [62]. MRI-based micro-FEA mechanical
parameters significantly decreased 6 months after kidney
transplantation, but structural parameters did not change
significantly by using micro-MRI only [59].
Reference Point Indentation

Reference point indentation (RPI) is a less invasive
measure of bone material strength (BMS) compared to
bone biopsy. The RPI instrument performs bone indentation testing by inserting a probe assembly through skin
and subcutaneous tissues directly onto the surface of the
bone after displacing the overlying periosteum in a very
small area. Microscopic fractures are then induced on the
surface of the bone, and bone mechanical properties at
tissue level are measured. Local infection and edema may
Kidney Dis
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preclude the use of these methods. People on anticoagulants need special attention to hemostasis [63]. Osteoprobe is a newer version of RPI that measures bone material properties by evaluating the BMS index without displacing the periosteum or using a reference probe [64,
65]. Patients with atypical femoral fractures have significant abnormalities in BMS measurements using the RPI
methods despite having normal DEXA-BMD scores [66].
Bone Biopsy and Histopathology

Bone biopsies are performed at the anterior iliac crest
after double tetracycline labeling [67]. For diagnostic
purposes, pathologists perform a qualitative comprehensive assessment of the bone specimens [67, 68]. In addition, for research purposes, quantitative histomorphometric analysis of bone sections may be used. Furthermore, bone quality and mechanical properties can be
evaluated using various methods such as Fourier transform infrared (FTIR) spectroscopy, FEA, and nano-, micro- and macro-indentation [69, 70].
In 2006, the Kidney Disease: Improving Global Outcomes (KDIGO) introduced the notion that bone histological abnormalities in patients with CKD should be
characterized by bone turnover, mineralization, and volume [71]. Bone turnover is classified as low, normal, or
high. Mineralization is characterized as normal or abnormal, and volume as low, normal, or high. The “abnormal”
mineralization may include defective or precipitous diffuse mineralization as in woven osteoid [72]. This classification should help the clinicians to focus on correcting
the bone abnormalities observed in their patients and direct appropriate therapies.
In patients with CKD stages 2–5 before dialysis, various abnormalities have been described ranging from mild
increase in bone turnover resulting from moderate SHPT,
with or without mineralization defect [73–75], to various
degrees of LTBD [76]. In an ongoing study, we found that
the majority of adult patients with CKD stages 2–5 predialysis have low or low-normal bone turnover without
mineralization defect. When patients reach ESRD, the
bone abnormalities usually intensify. The spectrum of
ROD histological features is very wide and has evolved
over time. Traditionally, the various forms of ROD encompass predominant SHPT, adynamic bone disease,
low turnover osteomalacia, and mixed uremic osteodystrophy. Predominant SHPT bone disease is characterized
by HTBD with increased formation and resorption surfaces. Osteoid volume and surface are high with numer6
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ous irregular osteoblasts and osteocytes. In some areas,
osteoid and mineralized bone lose their normal lamellar
structure and become irregularly “woven.” The resorption surfaces are high and resorption lacunae are deep
with abundant multinucleated large osteoclasts. In addition, formation and resorption surfaces may be covered
by peritrabecular fibrosis, which can extend deeply into
the bone marrow. Under fluorescent light, the extent of
tetracycline double labeling is high and may show diffuse
uptake in woven osteoid. The cancellous bone volume/
tissue volume may be low, high, or normal, whereas cortical bone exhibits a high degree of porosity.
At the other end of the spectrum, patients may present
with adynamic bone disease, where bone turnover is very
low with paucity of bone formation sites and osteoblasts.
Osteoid volume and surface are low with thin osteoid
seams. Osteoid and bone are mostly lamellar but may
show some remnants of woven structure from previous
overactivity. Similarly, bone resorption surfaces may vary
from low to slightly elevated. Under fluorescent microscopy, the mineralizing surfaces are mainly low with few
thin passive single labels. Cancellous bone volume and
cortical thickness are usually low.
Low-turnover osteomalacia in CKD patients is characterized by a severe mineralization defect with very high
volume and surface of osteoid and wide osteoid seams.
There is a paucity of osteoblasts. Resorption surfaces and
osteoclasts may be seen on the few bone surfaces not covered with osteoid. The tetracycline uptake is minimal and
consists of few thin single labels. This usually happens in
patients with aluminum toxicity, where aluminum can be
seen at the mineralization front. The cancellous bone volume and cortical thickness and porosity may vary from
low to elevated.
Mixed ROD represents a combination of various degrees of SHPT along with signs of mineralization defect (osteomalacia). Bone volume and cortical thickness may vary.
The spectrum of bone diseases has evolved over the
years [77]. In the early 1980s, there was a predominance
of mixed ROD and low turnover osteomalacia (in the
most severe cases) due to aluminum intoxication in ESRD
patients. With prevention of aluminum toxicity in the
subsequent years, the main histological forms of ROD
consisted of various degrees of SHPT bone diseases. In
the mid-1980s, the frequency of “aplastic” [78] or adynamic [79] bone disease increased significantly. Moreover, there are differences in the prevalence of the various
histological forms of ROD between black and white patients with CKD. Black patients are less prone to develop
LTBD and low bone volume [72, 73, 80–82].
Asadipooya/Abdalbary/Ahmad/Kakani/
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In post-kidney transplant patients, several factors influence bone diseases such as pre-existing ROD, immunosuppressive therapy, and suboptimal kidney function.
One of the prominent effects of renal transplantation is
bone loss [83] with low bone volume/tissue volume and
decrease in bone turnover [84–86]. Focal or generalized
mineralization defects are also not uncommon [85].
Bone histomorphometry is mainly used for research
[87, 88]. The parameters that characterize bone turnover
include bone formation rate/bone surface and activation
frequency as well as number of osteoblasts and osteoclasts. Bone formation rate/bone surface relates exclusively to the level of bone formation, whereas activation
frequency includes also parameters of bone resorption
and quiescent periods and indicates the frequency at
which the bone is completely renewed. Defective mineralization is defined as osteoid thickness >20 μm and mineralization lag lime >100 days. Volume encompasses
cancellous bone volume/tissue volume, trabecular thickness, and separation as well as cortical thickness and porosity. Normal values vary by age, gender [89, 90], and
race.
FTIR Spectroscopy

FTIR provides another way to measure bone quality
on bone biopsy specimens. The chemical bonds between
the components of bone matrix and mineralized bone,
like all chemical bonds, undergo vibrations. The parameters of FTIR spectroscopy pertinent to bone material
properties that are measured include (a) mineral to matrix ratio, (b) mineral maturity/degree of crystallization,
(c) collagen cross-linking ratio (the relative proportion of
mature to immature collagen), and (d) carbonate/phosphate ratio [91].
Malluche et al. [92] previously reported that mineral
to matrix ratio is lower in dialysis patients with HTBD.
This finding on FTIR in patients with HTBD correlated
with lower hardness, as measured by nano-indentation
techniques. There is shortened duration of remodeling
cycle in HTBD, and this can lead to diminished duration
of mineralization. This interferes with bone quality and
leads to decreased bone stiffness [92]. In LTBD dialysis
patients, there was no reduction in mineral to matrix ratio
compared to normal controls. Hardness measured by nano-mechanical properties in this group was not decreased. However, the microstructural properties of bone,
as measured by histomorphometry, such as trabecular
volume and thickness were noted to be lower [92].
Assessment of Bone Quality in CKD
Patients

When combined with histological evaluation of the
bone, FTIR can add valuable information on the bone
material properties. As another example, changes in collagen cross-link ratio strongly suggest that factors other
than bone turnover may be playing a role in the clinically
manifested fragility. FTIR technique is not widely available, and it needs human tissue from a bone biopsy. FTIR
can only measure relative quantities of minerals and matrix and the varying cross-link types and no absolute
quantitation can be provided.
Micro-Computed Tomography

Micro-computed tomography is an ex vivo technique
used to image small (millimeter-sized) bone samples using high amounts of radiation and can provide high-resolution 3D bone microstructural data [10]. It is not a clinically available technique but is considered the gold standard for measurement of bone structure against which
other in vivo modalities are usually compared [57]. Sharma et al. [93] reported that micro-computed tomography
was able to detect the deterioration of cortical microarchitecture in CKD patients. Of note, their cohort of patients did not have trabecular abnormalities.
Conclusion

CKD-induced bone quality and quantity abnormalities are complex disorders that confer high morbidity and
mortality in the CKD population. Proper diagnosis of the
actual underlying skeletal problems helps to prevent future bone loss and fractures. Once the diagnosis of ROD
has been established, knowing the bone quality and turnover abnormality could help predict the fracture risk.
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